Kraft Heinz enters the week with an unusual combination: a CEO who bought nearly $5 million of stock in May, a short position that has been quietly unwinding for weeks, and a stock price that still sits 24% below where that bet was placed — the tension between insider conviction and stubborn market skepticism defines this setup.
The most striking data point in the snapshot is CEO Steve Cahillane's open-market purchase in May — 213,106 shares at $23.46, worth just under $5 million. That stands out in an insider ledger otherwise dominated by routine awards and small executive sales. Net insider activity over the past 90 days runs to roughly $5.4 million in net buying, almost entirely driven by that single transaction. At $25.32, the stock is up modestly from Cahillane's cost basis, but the conviction signal is clear: the person running the company was a buyer when others were still selling.
Short sellers, meanwhile, have been stepping back. Short interest has fallen from a recent peak around 92-93 million shares in early August to roughly 87 million now — a drop of about 5% over the month — leaving SI running at 7.4% of the free float. Borrow remains cheap at 0.47%, down 11% on the week, with no squeeze pressure anywhere in the lending market. Availability is loose at 393%, meaning there are nearly four shares available to borrow for every one already out on loan — well above the 52-week floor of 251%. The ORTEX short score has also ticked down to 60.2 from 62.6 a week ago. Shorts are not capitulating, but they are trimming. Options positioning adds nothing alarming: the put/call ratio sits right at its 20-day average of 0.58, essentially flat, with no directional bias from the options market.
The Street's read is cautious but incrementally improving. Following the Q2 print on August 5 — which sent the stock down 6.3% on the day and nearly 8% over the following week — analysts lifted price targets almost across the board while leaving ratings unchanged. Barclays moved its target from $25 to $26. UBS went to $27. TD Cowen raised to $22. The direction of travel was universally higher, but every firm held neutral-to-negative ratings: Equal-Weight, Hold, Neutral, In-Line. JP Morgan reiterated Underweight with a $22 target, reflecting the bear case directly — US retail sales running at -3.0%, a potential headwind from lower SNAP benefit outlays, and limited visibility on when North American organic sales return to growth. The mean price target of $25.09 sits almost exactly at the current price, which tells its own story: the Street sees fair value here, not a recovery. The EV/EBITDA multiple near 9.7x and a price-to-book under 0.85x suggest valuation is the one pillar bears can't easily attack. EPS momentum rankings are weak — 26th percentile on 30-day momentum — underscoring that estimate revisions remain a headwind even as targets have nudged up post-earnings.
The ownership structure adds a layer worth watching. Berkshire Hathaway holds 27.5% of shares outstanding and has not moved its position. That anchor — combined with modest additions from BlackRock, Vanguard, and UBS Asset Management — keeps the float tight and provides a structural floor beneath institutional selling pressure. Hamblin Watsa Investment Counsel added 9 million shares in the most recently reported period, a meaningful new position from a value-oriented manager, while Morgan Stanley trimmed by 5.5 million shares. The two-sided institutional flow mirrors the broader disagreement on the name. Among peers this week, GIS and CAG posted similar weekly gains of 4-5% while also selling off Monday, suggesting the sector bid was broad rather than KHC-specific.
The next earnings date is October 28. Between now and then, the question is whether short sellers continue reducing exposure as the stock stabilises near analyst targets, or whether fresh weakness in US consumer spending data renews conviction on the short side and reverses the recent unwind.
See the live data behind this article on ORTEX.
Open KHC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
